Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study-Reference-Cited by-同舟云学术

Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study

Published:2022-06-02 Issue:9 Volume:29 Page:1010-1016
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J of Urology

Author:

Shindo Tetsuya¹^ORCID,Maehana Takeshi¹^ORCID,Tanaka Toshiaki¹^ORCID,Hashimoto Kohei¹^ORCID,Kobayashi Ko¹^ORCID,Takahashi Atsushi²,Hotta Hiroshi³,Kunishima Yasuharu⁴,Taguchi Keisuke⁵,Tachiki Hitoshi⁶,Ito Naoki⁷,Matsukawa Masanori⁸,Kato Ryuichi⁹,Miyamoto Shintaro¹⁰,Hinotsu Shiro¹¹,Masumori Naoya¹^ORCID

Affiliation:

1. Department of Urology Sapporo Medical University School of Medicine Sapporo Japan

2. Department of Urology Hakodate Koseiin Hakodate Goryoukaku Hospital Hakodate Japan

3. Department of Urology Japanese Red Cross Asahikawa Hospital Asahikawa Japan

4. Department of Urology Sunagawa City Medical Center Sunagawa Japan

5. Department of Urology Oji General Hospital Tomakomai Japan

6. Department of Urology Steel Memorial Muroran Hospital Muroran Japan

7. Department of Urology NTT East Corporation Sapporo Hospital Sapporo Japan

8. Department of Urology Takikawa Municipal Hospital Takikawa Japan

9. Department of Urology Muroran City General Hospital Muroran Japan

10. Department of Urology Japanese Red Cross Kushiro Hospital Kushiro Japan

11. Department of Biostatistics Sapporo Medical University School of Medicine Sapporo Japan

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.14941

Reference31 articles.

1. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

2. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

3. Recent advances in medical therapy for metastatic urothelial cancer

4. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial

5. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients;Onodera T;Nihon Geka Gakkai Zasshi,1984

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis;Clinical & Experimental Metastasis;2023-06-13